FDA Approves Lipfendra for High Cholesterol Treatment

The FDA approved Lipfendra on July 16, 2026, as the first oral PCSK9 inhibitor for adults, showing a 56% to 59% reduction in LDL cholesterol in clinical trials.

Updated 2026 guidelines from the AHA and ACC suggest that over 50% of U.S. adults may now be eligible for statin therapy to manage cardiovascular risk.

A separate meta-analysis published on July 22 found that the twice-yearly medication inclisiran reduced LDL cholesterol by 49% more than a placebo in patients.